Meningiomas occurring during long-term survival after treatment for childhood cancer

Elaine Sugden1, Aliki Taylor2, Pieter Pretorius3, Colin Kennedy4 and Ranj Bhangoo5

136, North Hinksey Village, Oxford, OX2 0 NA, UK
2Birmingham University, Birmingham B15 2TT, UK
3Oxford University Hospitals, Oxford OX3 9DU, UK
4University Hospital Southampton, Southampton SO16 6YD, UK
5Kings College Hospital Foundation Trust, London SE5 9RS, UK

Corresponding author: Elaine Sugden. Email: elainesugden@doctors.org.uk

Summary
Childhood cancer is rare but improvements in treatment over the past five decades have resulted in a cohort of more than 30,000 long-term survivors of childhood cancer in the UK with more added annually. These long-term survivors are at risk of late effects of cancer treatment which replace original tumour recurrence as the leading cause of premature death. Second neoplasms are a particular risk and in the central nervous system meningiomas occur increasingly with increased radiation dose to central nervous system tissue and length of time after exposure, resulting in a 500-fold increase above that expected in the normal population by 40 years of follow up. This multidisciplinary author group and others met to discuss the issue. Our pooled information, and consensus that screening should only follow symptoms, was published online by the Royal College of Radiologists in 2013. We outline here the current knowledge and management of these neoplasms secondary to childhood cancer treatment.

Keywords
secondary meningiomas, radiation-induced secondary neoplasms, childhood cancer treatment, late effects

Introduction
Although cancer in children (0–14 years) accounts for only 0.5% of UK cancer incidence with an average of 1500 cases per year, there are now of the order of 33,000 adults in the UK who during childhood were treated for cancer and are classed as long-term survivors.1 The majority of childhood cancers cannot be cured by local treatment (surgery and/or radiotherapy) alone and 5-year survival in the late 1960s was only 28%. Since then the addition of multiagent cytotoxic chemotherapy and the routine availability and entry to clinical trials managed by the Children’s Cancer and Leukaemia Group, formerly the United Kingdom Children’s Cancer Study Group, have led to serial improvement in 5-year survival for childhood cancer. Seventy eight percent of those under 15 years at diagnosis now survive at least 5 years.2 Acute lymphatic leukaemia, the commonest malignancy in childhood and universally fatal before the use of cytotoxic chemotherapy, was the first to show improvement followed by other haematological malignancies and the solid malignancies of childhood.

The definition of ‘long-term survival’ varies between those alive 5 years from diagnosis and 5 years after the end of treatment. As yet, there are relatively few 50-year survivors but the number in each decade of survival continues to increase. However, the long-term survival cohort still has a shortened life span compared with the normal population. Between 5 and 10 years after diagnosis the major cause of death is from the persistence or recurrence of the original cancer. Increasingly, with lengthening time after treatment, complications resulting from the treatment itself take their toll and can affect every organ, tissue and system in the body.3

Second neoplasms different from the original treated cancer are the most common cause of death after recurrence and accrue steadily over time from end of treatment with a rapid increase after 30 years of follow up.3 Breast cancer after mantle radiotherapy for Hodgkin’s disease is well known and there are guidelines for screening.4 Sarcomas are more common than carcinomas and most are associated with radiotherapy.5 Consent for radiotherapy in children should involve detailed information about possible complications including the risk of second tumours.

The commonest site for second neoplasms in children treated in the UK is the central nervous system (CNS).5 These follow treatment for primary CNS tumours, which as a group are the commonest solid malignancy of childhood, prophylactic brain irradiation for acute lymphatic leukaemia which was routine in the 1970s and early 1980s and after head and neck radiation impinging on the base of the brain.
In a recent study, over half (55%) of second neoplasms following brain irradiation in children in the UK were meningiomas and 30% gliomas, occurring between 5 and 52 years after treatment (mean 20.5 years). After irradiation of a primary brain tumour there was a cumulative incidence for meningiomas of 6.3% by 40 years, representing a risk relative to the general population of approximately 500-fold.

**Methods**

As a result of this clear information a medical multi-specialty working group met, sponsored by the Royal College of Radiologists. We shared knowledge on epidemiology, diagnosis and management of meningiomas and debated whether or not routine screening of those at increased risk should be advised. Current knowledge on the subject was pooled and together with our recommendations was used to create the document: ‘Meningioma as a late effect of cancer treatment’ published online by the Royal College of Radiologists in April 2013.

What follows is a short summary of that document.

**Epidemiology**

Meningiomas, tumours of the meninges, the thin-layered membrane surrounding the brain, occur sporadically in the absence of known aetiology and overall are the commonest brain tumour. Their apparent incidence is increasing as more are registered and more are found incidentally with scanning and an ageing population. The most recent statistics from the United States Central Brain Tumour Registry confirm their rarity in childhood (0.1/100,000) and a strikingly increased incidence with age reaching 49/100,000 in over 85 year olds. Women have an approximately double incidence and there is an association with neurofibromatosis type 2. Since 2004 it has been mandatory to register unbiopsied tumours diagnosed on scanning; 98% of meningiomas in the most recent report were given a non-malignant code.

An increased incidence with radiation exposure has been recognized since the 1970s and has been seen in atomic bomb survivors, after scalp irradiation for tinea capitis, after full mouth dental X-rays (when doses were higher than now) and after cranial or spinal irradiation. Higher radiation doses and longer interval after irradiation increase the risk of meningioma development.

**Diagnosis**

Symptoms are of new neurological deficit, seizures, raised intracranial pressure, proptosis, cavernous sinus syndrome or a lump on the skull. These prompt a scan (CT or MRI) which shows a well-circumscribed dural-based contrast enhancing mass; multiple lesions can occur. The radiological appearance is usually characteristic although histopathology is necessary to distinguish between benign WHO grade I with low recurrence risk, atypical grade II with increased cellularity and mitoses, and anaplastic grade III with frank features of malignancy and the ability to invade other structures.

**Specific features of radiation-associated meningiomas**

While both sporadic- and radiation-induced meningiomas are usually benign, those associated with radiation show behaviour which reflects the finding that 20–40% of radiation-associated meningiomas compared with <10% sporadic meningiomas demonstrate atypical or malignant features. They are more likely to be invasive and to recur than sporadic ones and in addition are more likely to be multiple (5–15% vs. <5%). Both sporadic- and radiation-associated meningiomas can recur even after apparent total resection.

Cytogenetic differences are also seen. Deletions of chromosome 1 have been reported in over 75% of radiation-associated meningiomas compared with the more usual deletions of chromosome 22 seen in sporadic forms. Most series of radiation-associated tumours show a lower female preponderance than control groups and a younger mean age at presentation (30–40 years after radiation for solid tumours, 65 years for sporadic tumours).

**Management**

The options include watch and wait with serial scanning for asymptomatic cases picked up incidentally, surgery for accessible and radiotherapy for inaccessible sites. Complete and safe resection is often not possible because of the tendency for radiation-induced meningiomas to be multiple, invasive and atypical or malignant. In addition, surgical healing can be compromised when prior radiotherapy has left a relatively avascular scalp. When re-irradiation is necessary newer techniques such as stereotactic radiotherapy and intensity-modulated radiation treatment and alternative radiation modalities (e.g. Protons) might benefit.

**Long-term follow-up after childhood cancer**

While two-thirds of survivors of childhood cancer have one or more late effects and one-third are
Should routine scanning be suggested?

The group debated long and hard about formal screening with MRI scans for those at risk of meningioma development.

We agreed the importance of survivors being made aware of their risks and that symptoms should be reported. However, we concluded that the physical risks of a new neurological disability or healing problems associated with surgery, in addition to the psychological risks from knowledge of an asymptomatic but not easily resectable lesion, from repeated waits ‘in limbo’ for scan results and from finding indeterminate white matter changes which often follow radiation, outweighed any advantage in the early detection of an asymptomatic lesion.

In addition, although gliomas would also be detected by scanning there has been no demonstrable benefit from intervention when asymptomatic.

Declarations

Competing interests: None declared

Funding: The Royal college of Radiologists funded the group meeting and e-publication of the original document

Ethical approval: Not required because individual patient data are not included

Guarantor: ES

Contributorship: This paper was written by ES and commented on by AT, PP, CK and RB on behalf of those acknowledged below.

Acknowledgements: This paper was written by the authors on behalf of the other contributors to and facilitators of the original document: Adrian Crellin, Omar al-Salihi, Olaf Ansorge, Andrew Toogood and Heidi Traunecker

Provenance: Not commissioned; peer-reviewed by Omar Pathmanaban

References

1. CRUK Cancer Statistics, see: http://www.cancerresearchuk.org/cancer-info/cancerstats/childhoodcancer/follow-up/childhood-cancer-statistics-trends (accessed 24 February 2014).

2. CRUK Cancer Statistics, see: http://www.cancerresearchuk.org/cancer-info/cancerstats/childhoodcancer/survival/childhood-cancer-survival-statistics (accessed 24 February 2014).

3. Reulen RC, Winter DL, Lancashire ER, et al. Long term cause-specific mortality among survivors of childhood cancer. JAMA 2010; 304: 172–179.

4. Screening women at higher risk. NHS breast Cancer Screening Programme, see: http://www.cancerscreening.nhs.uk/breastscreen/higher-risk.html (accessed 24 February 2014).

5. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB and Stevens MCG. Long term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004; 91: 1905–1910.

6. Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010; 28: 5287–5293.

7. Meningioma as a late effect of cancer treatment, a working group document. Royal College of Radiologists e-publication 2013, see: http://www.rcr.ac.uk/docs/oncology/pdf/BFCO(13)2_meningioma.pdf (accessed 24 February 2014).

8. Ostrom QT, Gittleman H, Farah P et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, 2006–2010. Neuro-Oncology 2013; 15, http://neuro-oncology.oxfordjournals.org/content/15/suppl_2.toc

9. Gutmann DH. The neurofibromatoses: when less is more. Hum Mol Genet 2001; 10: 747–755.

10. Preston DL, Ron E, Yonehara S, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst 2002; 94: 1555–1563.

11. Sadetzki S, Flint-Richter P, Ben-Tal T, et al. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 2002; 97: 1078–1082.
12. Preston-Martin S, Paganini-Hill A, Henderson BE, et al. Case control study of intracranial meningiomas in women in Los Angeles County, California. *J Natl Cancer Inst* 1980; 65: 67–73.

13. Goshen Y, Stark B, Kornreich L, et al. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2007; 49: 294–297.

14. Perry A, Louis DN, Scheithauer BW, et al. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD and Cavenee WK (eds) *World Health Organization Classification of Tumours of the Central Nervous System*, 4th edn. Lyon: IARC Press, 2007, pp.163–172.

15. Al-Mefty O, Topsakal C, Pravdenkova S, et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. *J Neurosurg* 2004; 100: 1002–1013.

16. Umansky F, Shoshan Y, Rosenthal G, et al. Radiation-induced meningioma. *Neurosurg Focus* 2008; 24: E7.

17. Yano S and Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. *J Neurosurg* 2006; 105: 538–543.

18. Debus J, Wyendrich M, Pirzkall A, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. *Clin Oncol* 2001; 19: 3547–3553.

19. Pirzkall A, Debus J, Haering P, et al. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. *Int J Radiat Oncol Biol Phys* 2003; 55: 362–372.

20. Weber DC, Schneider R, Goitein G, et al. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys* 2012; 83: 865–871.

21. Oeffinger K, Mertens AC and Sklar CA. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med* 2006; 355: 1572–1582.

22. Taylor A, Hawkins M, Griffiths A, et al. Long-term follow-up of survivors of childhood cancer in the UK. *Pediatr Blood Cancer* 2004; 42: 161–168.

23. Reulen RC, Winter DL, Lancashire ER, et al. Health-status of adult survivors of childhood cancer: a large-scale population-based study from the British Childhood Cancer Survivor Study. *Int J Cancer* 2007; 121: 633–640.

24. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2008; 100: 1368–1379.

25. Glaser A, Levitt G, Morris P, Trapp J, Gibson F on behalf of the Children and Young People workstream of the National Cancer Survivor Initiative (NCSI), UK. Enhanced quality and productivity of long-term aftercare of cancer in young people. *Arch Dis Child.* doi:10.1136/archdischild-2013-304348.

26. Long term follow up of survivors of childhood cancer. *Scottish Intercollegiate Guidelines Network number 132 March 2013*, http://www.sign.ac.uk/pdf/sign132.pdf (accessed 24 February 2014).